VIICTR
Profiles
ORIT
Pediatrics CRA
Home
About
Overview
Sharing Data
ORCID
Help
History (1)
A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.
A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma. Ann Oncol. 2017 04 01; 28(4):804-808.
View in:
PubMed
subject areas
Aged
Aged, 80 and over
Antineoplastic Agents
Carcinoma, Renal Cell
Disease-Free Survival
Everolimus
Female
Heterocyclic Compounds, 3-Ring
Humans
Kidney Neoplasms
Male
Middle Aged
Treatment Outcome
authors with profiles
NIZAR M TANNIR
ERIC JONASCH